Cover key Japan regulatory topics on drugs, medical devices and ATMPs

Key Topics on Japan Regulatory Affairs (Drugs, Medical Devices, ATMPs)

Phase I

Overview of Japanese Phase I Trials

In order to advance discussions related to drug regulations with the aim of eliminating drug lag/drug loss and strengthe...

Recent Posts

Notification of necessity for Japanese data when applying for drug approval (dated October 23, 2024)

Overview of Japanese Phase I Trials

Gate Opening Summit for Innovative Drug Discovery (on July 30, 2024), and Strategic Goal and Action Plan for Improving Drug Discovery Capabilities to Support Early Availability of Innovative Drug

Notification of Use Results Survey and Administrative Notice (dated July 18, 2024)

Japanese Website: “Basics of Medical Program Development”

Popular Articles

Changes in the timing of new drug approvals/drug price listings in Japan (from January 2025)

2024.09.232024.11.10

The Roles of the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA)

US approval of self-administered nasal influenza vaccine (September 20, 2024)

Drugs: Pilot of change procedures for moderate risk changes of manufacturing method (from September 27, 2024)

Overview of Japanese Phase I Trials

Archives

November 2024
October 2024
September 2024

Categories

ATMPs
Basic
Drugs
Drugs, Medical Devices, ATMPs
Medical Devices

Key Topics on Japan Regulatory Affairs (Drugs, Medical Devices, ATMPs)

About us
Privacy Policy
Contact

© 2024 Key Topics on Japan Regulatory Affairs (Drugs, Medical Devices, ATMPs).

Home
Search
Top
Sidebar